Taksta

Taksta (previously CEM-102) is a front-loaded oral dosing regimen of sodium fusidate under development in the U.S. as an antibiotic for gram-positive infections including drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).[1]

Clinical trials

Jan 2010: Taksta has completed enrollment in a Phase 2 trial (due to run until March 2010) and is preparing for Phase 3 studies in the U.S. for acute bacterial skin structure infections (being compared with Linezolid). [2]

Sep 2010: Taksta demonstrated comparable clinical success rates compared to linezolid in a Phase 2 trial in the U.S. for acute bacterial skin and skin structure infections.[3]

Jun 2011: Taksta may be effective in the treatment of chronic prosthetic joint infections and osteomyelitis.[4]

See also

References

  1. ↑ "Cempra Announces Expansion of Clinical Management Team to Advance Leading Antibacterial Clinical Programs TAKSTA(TM) and CEM-101".
  2. ↑ "Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections".
  3. ↑ Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Still JG, Das A, Fernandes P (2011). "A randomized, double-blind Phase 2 study comparing the efficacy and safeety of an oral fusidic acid loading-dose regimen to oral linezolid in the treatment of acute bacterial skin and skin structure infections." Clinical Infectious Diseases 52(Supplement 7):S520-S226.
  4. ↑ Wolfe CR. (2011) "Case report: treatment of chronic osteomyelitis." Clinical Infectious Diseases 52(Supplement 7):S538-S541.


This article is issued from Wikipedia - version of the 5/14/2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.